Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imugene ( (AU:IMU) ) has issued an announcement.
Imugene has announced the resignation of Chief Operating Officer Dr Bradley Glover, who is stepping down to focus on other business interests after playing a key role in advancing the company’s oncology programs, particularly the development of its CAR T cell therapy azer-cel. The company stated that responsibilities will be transitioned without disrupting operations or ongoing programs, and the board has publicly thanked Dr Glover for his contributions, signalling a managed leadership change designed to preserve momentum across its clinical pipeline and reassure investors and partners about continuity.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a Sydney-based, clinical-stage immuno-oncology company developing novel immunotherapies designed to activate cancer patients’ immune systems to treat and eradicate tumours. Its pipeline includes azer-cel (azercabtagene zapreleucel), an allogeneic CAR T cell therapy targeting CD19 for blood cancers, and the CF33 oncolytic virotherapy platform aimed at a range of cancers, often in combination with standard-of-care drugs and emerging immunotherapies. Supported by an international team of cancer experts, Imugene is positioning its therapies as potential foundation treatments in the rapidly growing global cancer immunotherapy market.
Average Trading Volume: 1,817,800
Technical Sentiment Signal: Sell
Current Market Cap: A$115.7M
See more insights into IMU stock on TipRanks’ Stock Analysis page.